Data from China’s Ministry of Health show that there are currently about 120 million chronic asymptomatic hepatitis B virus carriers and about 30 million chronic hepatitis B patients in China. The annual economic loss caused by chronic hepatitis B (including cirrhosis and liver cancer) in China amounts to about RMB 915.1 billion, which is equivalent to the salary of 225 million people. In the treatment process, most hepatitis B virus carriers lack correct understanding of the virus carriage status and there are many misconceptions. Some chronic hepatitis B patients or hepatitis B virus carriers have frequent blood tests in the treatment, blindly antiviral treatment without regard to indications, and some people fall for false advertisements, believing that hepatitis B can be cured and use drugs indiscriminately. At the same time, there are more and more new tests for hepatitis B patients, and some patients are tested more than ten times a year. In fact, not every patient needs to have these indicators checked once. The common misconceptions of hepatitis B patients and hepatitis B virus carriers 1, mistaking hepatitis B as a marker, commonly known as “two pairs of half” positive people as hepatitis B patients. The carrier’s liver function is normal and he can study, work and live normally. 2, the excessive pursuit of negative, hepatitis B markers positive can only indicate the infection of hepatitis B virus, to a certain extent, shows the level of virus replication in the body. For carriers, HBeAg and HBsAg are not pathogenic and do not reflect the extent of liver lesions. The carrier’s organism is in a state of immune tolerance to the hepatitis B virus, when various antiviral treatments are ineffective, which not only causes unnecessary financial burden, but may also cause adverse reactions. Carriers of hepatitis B virus are under medical observation, and the Guidelines for the Prevention and Treatment of Chronic Hepatitis B do not advocate antiviral treatment for them, but the survey found that most carriers of hepatitis B virus have received or are receiving one or another treatment. It has been proven that the disorganized treatment methods have limited effect and not only increase the economic burden of patients, but also can lead to drug-related liver damage. The current internationally accepted goal of treating chronic hepatitis B: delaying the progression of hepatitis to cirrhosis or liver cancer At present, there is no satisfactory treatment for hepatitis B worldwide, and some illegal medical advertisements generally advocate the conversion of “major triplets” to “minor triplets”. Some illegal medical advertisements generally advocate the conversion of “major triplet” to “minor triplet” and “minor triplet” to all negative. At this stage, there is no treatment that has the efficacy of “curing” or “eradicating” chronic hepatitis B. It is known that the current internationally accepted goal of treating chronic hepatitis B is to delay the progression of hepatitis into cirrhosis or liver cancer. According to the latest medical concepts, the major and minor triplets do not necessarily have to be treated, but only those patients whose transaminases are elevated more than two times the normal value should be considered for treatment. Most people infected with hepatitis B may carry the virus for the rest of their lives without developing the disease, and only a few infected people develop chronic hepatitis. However, most patients will get better after treatment by doctors and can study and work normally. According to the relevant regulations in China, except for some colleges and universities when enrolling students and schools and units when recruiting workers, except for positions in the catering industry and kindergarten education, they cannot reject people who are AoA-positive, and most hepatitis B virus carriers should have the right to work, study and enjoy married life normally. To further accelerate the process of hepatitis B control, it is necessary to strengthen hepatitis B vaccination for newborns while providing catch-up vaccination for children and adolescents who have missed hepatitis B vaccination, and to start immunization for vulnerable adult high-risk groups to provide maximum protection against hepatitis B virus infection. The treatment of hepatitis B is a systematic and long-term project, and it is important to go to a regular hospital and find a professional physician for scientific diagnosis and targeted treatment, and not to take so-called “special drugs” that are not officially approved by the state, so as not to delay treatment and aggravate the original condition. The following points should be noted: 1. Establish a health file Regularly go to the hospital to check the indicators of HBV, liver function, ultrasound, etc., generally once every six months. Found to have e antigen positive, HBVDNA positive indicates a strong infectious, at this time, if the liver function abnormal, should be further treatment. Must be scientific treatment persistent. 2, reasonable nutrition, maintain an optimistic attitude. 3, limit smoking and alcohol, avoid using drugs that damage liver function. 4, pay attention to the combination of work and rest, do not overwork, life, work should be regular.